FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC Summary: The FDA approved zidesamtinib for previously treated ROS1-positive lung cancer, offering a promising targeted therapy with durable responses and strong activity against brain metastases. Click to see the full article Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects Summary: Researchers identified […]